AUTHORS
Laura Frances Walsh, MD, K. Rappazzo2, Hua-Ling Tsai3, Alexander Joseph Ambinder, MD, MPH4, Ravi Varadhan, PhD5, Venkata Preetam Sandeep Kaduluri, MBBS, MPH6, Rena Xian, MD7, Amy DeZern, MD, MHS8, Richard John Jones, MD9, Philip Imus, MD10, Richard Ambinder, MD, PhD11
AFFILIATIONS
1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
3 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
4 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
5 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
6 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
7 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
8 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
9 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
10 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
11 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
ABSTRACT
Introduction Historically, in allogeneic hematopoietic cell transplantation (alloHCT), Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disorder (PTLD) was a significant, often fatal complication. Calcineurin inhibitors and T-cell depletion were implicated as risk factors. With widespread use of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis, EBV-PTLD is rare, though detection of EBV DNA in plasma remains common. Unlike other human herpesviruses in alloHCT, the clinical significance of EBV DNAemia in the absence of PTLD remains underexplored. We evaluated whether early or late EBV DNAemia associates with mortality and identified risk factors for EBV DNAemia.
Methods From January, 2018, we prospectively monitored non-myeloablative alloHCT recipients ≥18 yo receiving PTCy at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Patients received tacrolimus or sirolimus (D5 to ≥D60) and mycophenolate (D5–D35). Weekly plasma EBV DNA assessments occurred from D0–D60. Routine EBV serology and preemptive rituximab for EBV DNAemia are not standard; however, B-cell lymphoma patients occasionally received rituximab after D30. After D60, EBV monitoring was performed at provider discretion. EBV DNAemia was defined as plasma EBV DNA >50 IU/mL. Patients were analyzed in two prespecified groups: Early (monitored D0–D60) and Late (monitored beyond D60). Early EBV DNAemia and overall survival (OS) associations were evaluated using multivariable Cox proportional hazards models adjusted for patient age, donor age, risk category, and malignancy status. Analyses of late EBV DNAemia additionally adjusted for EBV testing frequency and interval since the last test.
Results A total of 1,280 patients (40% bone marrow, 60% peripheral blood; malignant disease, 92.4%; aplastic anemia, 4.9%; and hemoglobinopathy, 1.8%) underwent weekly monitoring from D0–D60. Patients had a median of 8 tests (IQR 8-9) during this period. Of these, 797 patients were monitored at irregular intervals beyond D60 (median 3 tests, IQR 1-6). With a median follow-up of 3.6 years, the 3-year OS was 71%. Early EBV DNAemia occurred in 79 of 1,280 patients (6%) and was not associated with OS (HR 1.13, 95% CI:0.78-1.64, P = 0.52). Among patients monitored beyond D60, 138 of 797 (17%) developed late EBV DNAemia. In a time-dependent multivariable Cox model, late EBV DNAemia was independently associated with increased mortality (HR 1.92, 95% CI: 1.26-2.94, P = 0.003). Increased testing frequency after D60 was independently associated with mortality, consistent with greater monitoring in clinically unwell patients (HR 1.08 per additional test, p<0.001). However, the association between late EBV DNAemia and inferior survival persisted even after this adjustment. Only one EBV-positive PTLD case was observed, occurring on D165. Two patients received rituximab pre-emptively for late DNAemia. Neither developed PTLD. One went on to die from multiorgan failure and one is alive and well. Univariable analysis indicated no associations with stem cell source or acute GVHD. Patients receiving grafts from mismatched unrelated donors had borderline higher rates of late EBV DNAemia than those receiving grafts from fully matched unrelated donors (1-year cumulative incidence, 19% vs. 10%; P = 0.049). Among deaths, relapse or disease progression accounted for 45% in those with early EBV DNAemia and 44% in those without it; organ failure for 16% and 14%, respectively; infection 13% and 9%; GVHD 3% and 5%. Relapse or disease progression accounted for 47% with late EBV DNAemia and 48% without; GVHD 11% and 5%; infection 10% and 4%, respectively.
Conclusions We confirmed that among alloHCT recipients receiving PTCy, PTLD is rare. Early EBV DNAemia was not associated with post-transplant mortality and routine weekly monitoring before D60 may not be useful with PTCy in adults. In contrast, late EBV DNAemia (beyond D60) was independently associated with increased mortality. Limitations include that this was a single center study and that patients with ongoing medical problems were more likely to be monitored beyond D60. Because relapse-related deaths occurred at similar frequencies regardless of EBV DNAemia status, these findings suggest that late EBV DNAemia may be associated with fatal GVHD and/or other infection.
DISCLOSURES
Laura Frances Walsh, MD: No relevant conflicts of interest to declare.